AMENDMENTS TO THE CLAIMS

1. (Canceled)

2. (Currently Amended) A method for the treatment ~~or prevention~~ of thrombocythemia in a patient with thrombocythemia comprising transdermally administering to said patient an effective amount of a skin permeable form of anagrelide or a pharmaceutically acceptable salt of anagrelide ~~in a manner avoiding~~ to minimize first pass liver metabolism~~, wherein the anagrelide or anagrelide salt is administered by implant, sublingual, pregastric, pessary, suppository, transdermal, nasal spray, inhaled absorption or topical administration~~.

3. (Previously Presented) The method according to claim 2, wherein the anagrelide or anagrelide salt is administered with a skin permeation enhancer.

4. (Canceled)

5. (Canceled)

6. (Currently Amended) The method according to claim [[5]] 2, wherein the anagrelide or anagrelide salt is in the form of a reservoir formulation.

7. (Currently Amended) The method according to claim [[5]] 2, wherein the anagrelide or anagrelide salt is in the form of a single layer formulation comprising the anagrelide or anagrelide salt and at least one adhesive.

8. Currently Amended) The method according to claim [[5]] 2, wherein the anagrelide anagrelide salt is in the form of a multiple layer formulation wherein at least one layer of said multiple layer formulation comprises the anagrelide or anagrelide salt and at least one adhesive.

9. (Currently Amended) The method according to claim [[5]] 2, wherein the anagrelide or anagrelide salt is in the form of a matrix formulation.

10. (Canceled)

11. (Canceled)

12. (Previously Presented) The method according to claim 2, wherein said thrombocythemia is associated with essential thrombocythemia (ET), chronic myologenous leukemia (CML), polycythemia vera (PV), agnogenic myeloid metaplasia (AMM) or sickle cell anemia (SCA).

13. (Previously Presented) The method according to claim 2, wherein the anagrelide or anagrelide salt is administered in an amount of 0.1 to 20 mg/kg/day.

14. (Previously Presented) The method according to claim 2, wherein the anagrelide or anagrelide salt is administered in a daily dose of 0.5 to 3 mg.

15. (Previously Presented) The method according to claim 2, wherein the anagrelide or anagrelide salt is administered in a daily dose of 1 to 2 mg.

16. (Canceled)

17. (Currently Amended) The method according to claim [[5]] 2, wherein the anagrelide or anagrelide salt is in the form of a composition which further comprises at least one skin permeation enhancer.

18. (Currently Amended) The method according to claim 17, wherein said at least one skin permeation enhancer is linalool, carvacrol, thymol, citral, menthol, oleic acid, or t-anethole.

19. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch having a single-layer drug-in-adhesive system comprising a composition containing the anagrelide or anagrelide salt, one or more excipients, and at least one skin-contacting adhesive, which is combined with a single backing film.

20. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch having a multi-layer drug-in-adhesive system wherein: (a) said system comprises at least two distinct layers comprising the anagrelide or anagrelide salt and at least one adhesive, and a membrane between said at least two layers or (b) said system comprises at least two distinct layers comprising the anagrelide or anagrelide salt and at least one adhesive, and a single backing film.

21. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch having a reservoir transdermal system comprising a liquid compartment containing a solution or suspension of the anagrelide or anagrelide salt, a release liner, and between said release liner and said liquid compartment, a semi-permeable membrane and at least one adhesive.

22. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch having a matrix system comprising a semisolid matrix containing a solution or suspension of the anagrelide or anagrelide salt which is in direct contact with a release liner, and a skin adhesion component incorporated in an overlay which forms a concentric configuration around said semisolid matrix.

23. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch containing the anagrelide or anagrelide salt intimately distributed in a matrix.

24. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch containing 1 mg to 100 mg of the anagrelide or anagrelide salt per patch.

25. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch containing an amount of the anagrelide or anagrelide salt to provide a daily dose of 0.5 to 3 mg.

26. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch containing a composition comprising the anagrelide or anagrelide salt and an acrylic adhesive.

27. (Previously Presented) The method according to claim 26, wherein said composition contains 66 to 99.8% by weight acrylate adhesive.

28. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch containing an amount of the anagrelide or anagrelide salt, azone, ethanol, water, propylene glycol and Klucel HF.

29. (Previously Presented) The method according to claim 28, wherein administration is via a transdermal patch containing the anagrelide or anagrelide salt, 0.1 to 10 parts by weight azone, from 30 to 69.8 parts ethanol, 29 to 50 parts by weight water, from 0 to 30 parts by weight propylene glycol, and 1 to 5 parts by weight Klucel HF.

30. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch containing the anagrelide or anagrelide salt, ethanol, and Klucel HF.

31. (Previously Presented) The method according to claim 30, wherein administration is via a transdermal patch containing the anagrelide or anagrelide salt, 85 to 97 parts by weight ethanol and 2 to 14.9 parts Klucel HF.

32. (Currently Amended) The method according to claim [[5]] 2, wherein administration is via a transdermal patch having an area of 5 cm^2 to 100 cm^2.

33. (Previously Presented) The method according to claim 2, wherein the anagrelide or anagrelide salt is administered over a period of time of 1 to 7 days.

34. (Previously Presented) The method according to claim 2, wherein the anagrelide or anagrelide salt is administered over a period of time of 3 to 4 days.

35. (Canceled)

36. (Currently Amended) The method according to claim 3, wherein said method comprises: (a) contacting said area of skin with the anagrelide or anagrelide salt and [[a]] the skin permeation enhancer; and (b) maintaining said source in material transmitting relationship to said area of skin for a period of at least 12 hours.

37.-49. (Canceled)